Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore

Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent

Glenmark Pharmaceuticals
The revenues dipped by 6.3 per cent year-on-year (YoY)
Sohini Das Mumbai
1 min read Last Updated : Aug 10 2022 | 11:49 PM IST
Mumbai-headquartered Glenmark Pharmaceuticals posted a 31 per cent decline in net profit for the first quarter of the financial year to Rs 211.1 crore, as the consolidated revenues dipped from Rs 2,965 crore in the previous corresponding quarter to Rs 2,777.3 crore in Q1FY23. The results were declared after market hours.

The revenues dipped by 6.3 per cent  year-on-year (YoY), but the company said that when viewed without taking into account the global sales of Covid-related products in the first quarter of FY 2021-22, the base business showed a YoY growth of 10.4 per cent in the current fiscal.

Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent. “Reported Ebidta was Rs 431.6 crore in the quarter ended June 30, 2022, with margins of 15.5 per cent,” the company said in  a statement.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Glenmark PharmaceuticalsQ1 resultspharma sctors

Next Story